As a result of the performance in the second quarter of 2012, Merck is updating its forecast for FY 2012. Merck expects the markets for pharmaceuticals as well as over-the-counter drugs to grow driven by volumes in Emerging Markets. For its Liquid Crystals products, the company expects volumes to remain strong in the third quarter and a softer demand in the fourth quarter, also as a result of some normalization of its currently high market share. Finally, Merck continues to see solid demand for Life Science products, driven also by continued volume growth in biologic-based drugs.
Based on these assumptions, Merck expects the following financial performance of its businesses for FY 2012:
| XLS |
|
Guidance FY 2012 | ||||
|
|
|
| ||
|
|
|
| ||
|
|
|
| ||
|
Merck Divisions |
€ million |
EBITDA pre one-time items | ||
| ||||
|
Merck Serono |
|
~ 1,750 – 1,800 | ||
|
Consumer Health |
|
~ 60 – 65 | ||
|
Performance Materials |
|
~ 660 – 680 | ||
|
Merck Millipore |
|
~ 580 – 600 | ||
|
Corporate and Other |
|
~ – 200 | ||
|
|
|
| ||
|
|
|
| ||
|
Merck Group |
€ billion |
| ||
|
Total revenues |
|
~ 10.7 | ||
|
EBITDA pre one-time items* |
|
2.85 – 2.95 | ||
FX assumptions for the second half of 2012:
€/US$ = 1.25
€/CHF = 1.20
back
